Lupagen

Lupagen is pioneering an extracorporeal bedside delivery platform aimed at transforming the administration of cell and gene therapies. Its Xynvivo™ System enables a simplified, potentially lower-cost process that can be applied to both ex vivo cell therapy and in vivo gene therapy programs, addressing critical industry pain points like high manufacturing costs, complex logistics, and safety concerns related to systemic vector administration. By offering a combination of proprietary technology and collaborative services from preclinical through commercial stages, Lupagen seeks to expand patient access and provide biopharma partners with a differentiated and accelerated path to market.

Xynvivo™ System: An extracorporeal, closed-loop medical device that performs bedside collection, viral vector/nanoparticle binding to patient cells, and reinfusion in a single procedure, enabling in-situ gene therapy.

Lupagen occupies a niche focused on extracorporeal bedside delivery. Potential competitors include other point-of-care manufacturing systems (e.g., from Miltenyi Biotec, Cytiva) and companies developing improved viral vectors or non-viral delivery methods that aim to solve similar cost and safety challenges. Its primary competition is the entrenched paradigm of centralized ex vivo manufacturing.